Randomised, placebo-controlled, double-blind, double-dummy, multicentre trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine: the ECSMOKE trial protocol

Ivan Berlin, Bertrand Dautzenberg, Blandine Lehmann, Jessica Palmyre, Emmanuelle Liégey, Yann De Rycke, Florence Tubach, Ivan Berlin, Bertrand Dautzenberg, Blandine Lehmann, Jessica Palmyre, Emmanuelle Liégey, Yann De Rycke, Florence Tubach

Abstract

Introduction: Electronic cigarettes (EC) mainly with nicotine content are widely used worldwide. Although the number of publications about its use is increasing exponentially, evidence-based, unbiased, conclusive, head-to-head comparisons about its efficacy and safety as an aid for smoking cessation are lacking. METHODS AND ANALYSIS: Design: randomised, placebo and reference treatment-controlled, multicentre, double-blind, double-dummy, parallel-group trial. Participants: smokers smoking at least 10 cigarettes/day in the past year and motivated to quit, aged 18-70 years. Interventions: (A) EC without nicotine (ECwoN) plus placebo tablets of varenicline administered by oral route: placebo condition, (B) EC with nicotine (ECwN) plus placebo tablets of varenicline: ECwN condition. Voltage regulated EC will be used with liquid containing 12 mg/mL of nicotine for ad libitum use. Flavour: blond tobacco. (C) Reference: ECwoN plus 0.5 mg varenicline tablets: varenicline condition. Varenicline administered according to the marketing authorisationauthorisation. Treatment duration: 1 week+3 months. Primary outcome: continuous smoking abstinence rate (CAR) (abstinence from conventional/combustible cigarettes) during the last 4 weeks (weeks 9-12) of the treatment period defined as self-report of no smoking during the previous 2 weeks and expired air carbon monoxide ≤8 at visit 4 at week 10 after target quit date (TQD), that is, 11 weeks after treatment initiation AND at visit 5, week 12 after TQD, that is, 13 weeks after treatment initiation. Secondary outcomes: safety profile; point prevalence abstinence rate; CAR confirmed by urinary anabasine concentration; changes in cigarettes/day consumption; craving for tobacco and withdrawal symptoms with respect of baseline.

Ethics and dissemination: The ethics committee approval was obtained on 17 April 2018. All data collected about the study participants will be anonymised. Investigators will communicate trial results to participants, health authorities, healthcare professionals, the public and other relevant groups without any publication restrictions.

Trial registration number: NCT03630614; Pre-results.

Keywords: electronic cigarettes; randomised, controlled, double dummy trial; smoking cessation; varenicline.

Conflict of interest statement

Competing interests: IB reports occasional honoraria from Pfizer in the last 3 years for counseling and presentations at meetings. FT is head of the clinical research unit of Pitié-Salpêtrière and Charles Foix hospitals and the pharmacoepidemiology center of Assistance Publique Hôpitaux de Paris, that have received research funding, grants and fees for consultant activities from a large number of pharmaceutical companies, that have contributed indiscriminately to the salaries of its employees. She did not receive any personal remuneration from these companies.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
The ECSMOKE trial’s outline.

References

    1. WHO. Tobacco Free Initiative. (Accessed 10 Sep 2018).
    1. Doll R, Peto R, Boreham J, et al. . Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519 10.1136/
    1. Jha P, Ramasundarahettige C, Landsman V, et al. . 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341–50. 10.1056/NEJMsa1211128
    1. Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014;370:60–8. 10.1056/NEJMra1308383
    1. Holford TR, Meza R, Warner KE, et al. . Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014;311:164–71. 10.1001/jama.2013.285112
    1. Official Journal of the European Union. Directive 2017/40/EU of the European Parliament and of the council of 3 April 2014. (Accessed 10 Sep 2018).
    1. Ordonnance n° 2016-623 du 19 mai 2016 portant transposition de la directive 2014/40/UE sur la fabrication, la présentation et la vente des produits du tabac et des produits connexes. 2014. (Accessed 10 Sep 2018).
    1. Shahab L, Goniewicz ML, Blount BC, et al. . Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. Ann Intern Med 2017;166:390–400. 10.7326/M16-1107
    1. The National Academies of Sciences, Engineering, Medicine. Public health consequences of e-cigarettes. 2018. (Accessed 10 Sep 2018).
    1. Farsalinos KE, Spyrou A, Stefopoulos C, et al. . Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). Sci Rep 2015;5:11269 10.1038/srep11269
    1. D’Ruiz CD, Graff DW, Yan XS. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. BMC Public Health 2015;15:991 10.1186/s12889-015-2349-2
    1. Wagener TL, Floyd EL, Stepanov I, et al. . Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tob Control 2017;26:e23–e28. 10.1136/tobaccocontrol-2016-053041
    1. Bullen C, McRobbie H, Thornley S, et al. . Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control 2010;19:98–103. 10.1136/tc.2009.031567
    1. Vansickel AR, Cobb CO, Weaver MF, et al. . A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev 2010;19:1945–53. 10.1158/1055-9965.EPI-10-0288
    1. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 2013;15:267–70. 10.1093/ntr/ntr316
    1. Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology 2014;231:401–7. 10.1007/s00213-013-3249-8
    1. El Dib R, Suzumura EA, Akl EA, et al. . Electronic nicotine delivery systems and/or electronic non-nicotine delivery systems for tobacco smoking cessation or reduction: a systematic review and meta-analysis. BMJ Open 2017;7:e012680 10.1136/bmjopen-2016-012680
    1. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med 2016;4:116–28. 10.1016/S2213-2600(15)00521-4
    1. Weaver SR, Huang J, Pechacek TF, et al. . Are electronic nicotine delivery systems helping cigarette smokers quit? Evidence from a prospective cohort study of U.S. adult smokers, 2015-2016. PLoS One 2018;13:e0198047 10.1371/journal.pone.0198047
    1. Bullen C, Howe C, Laugesen M, et al. . Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013;382:1629–37. 10.1016/S0140-6736(13)61842-5
    1. Caponnetto P, Campagna D, Cibella F, et al. . EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One 2013;8:e66317 10.1371/journal.pone.0066317
    1. McRobbie H, Bullen C, Hartman-Boyce J, et al. . Electronic cigarettes for smoking cessation and reduction. Review. The Cochrane Library 2014;12:CD010216.
    1. Hartmann-Boyce J, McRobbie H, Bullen C, et al. . Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2016;9:CD010216 10.1002/14651858.CD010216.pub3
    1. Hajek P, Phillips-Waller A, Przulj D, et al. . A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med 2019;380:629–37. 10.1056/NEJMoa1808779
    1. Bernstein SL. Electronic cigarettes: more light, less heat needed. Lancet Respir Med 2016;4:85–7. 10.1016/S2213-2600(16)00010-2
    1. Soar K, Kimber C, McRobbie H, et al. . Nicotine absorption from e-cigarettes over 12 months. Addictive Behaviors published online on 2018;19.
    1. Berlin I, Jacob N, Coudert M, et al. . Adjustment of nicotine replacement therapies according to saliva cotinine concentration: the ADONIS* trial-a randomized study in smokers with medical comorbidities. Addiction 2011;106:833–43. 10.1111/j.1360-0443.2010.03306.x
    1. Berlin I, Grangé G, Jacob N, et al. . Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014;348:g1622 10.1136/bmj.g1622
    1. Dawkins LE, Kimber CF, Doig M, et al. . Self-titration by experienced e-cigarette users: blood nicotine delivery and subjective effects. Psychopharmacology 2016;233:2933–41. 10.1007/s00213-016-4338-2
    1. Anthenelli RM, Benowitz NL, West R, et al. . Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507–20. 10.1016/S0140-6736(16)30272-0
    1. Cahill K, Lindson-Hawley N, Thomas KH, et al. . Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016;5:CD006103 10.1002/14651858.CD006103.pub7
    1. Cahill K, Stevens S, Perera R, et al. . Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;5:CD009329 10.1002/14651858.CD009329.pub2
    1. Haute Autorité de Santé. Arrêt de la consommation de tabac : du dépistage individuel au mentien de l’abstinence en premier recours. (Accessed 11 Sep 2018).
    1. Berlin I, Singleton EG, Heishman SJ. Validity of the 12-item French version of the tobacco craving questionnaire in treatment-seeking smokers. Nicotine Tob Res 2010;12:500–7. 10.1093/ntr/ntq039
    1. University of Vermont. Minnesota tobacco withdrawal scale. (Accessed on 11 September 2018).
    1. Marclay F, Saugy M. Determination of nicotine and nicotine metabolites in urine by hydrophilic interaction chromatography-tandem mass spectrometry: Potential use of smokeless tobacco products by ice hockey players. J Chromatogr A 2010;1217:7528–38. 10.1016/j.chroma.2010.10.005
    1. Société Française d’Alcoologie. Mésusage de l’alcool. Dépistage, diagnostic et traitement.. (Accessed 11 Sep 2018).
    1. Fiellin DA, Reid MC, O’Connor PG. Screening for alcohol problems in primary care: a systematic review. Arch Intern Med 2000;160:1977–89.
    1. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984;252:1905–7.
    1. Santé Publique France. Alcool et médecine générale. Recommandations cliniques pour le repérage précoce et les interventions brèves. (Accessed 11 Sep 2018).
    1. Casagrande JT, Pike MC, Smith PG. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34:483–6. 10.2307/2530613
    1. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics 1977;33:593–602. 10.2307/2529457
    1. Code de la Santé publique. Article R1123-46. 2016. (Accessed 12 Sep 2018).
    1. Code de la santé publique. Article L1123. 2018. (Accessed 12 Sep 2018).
    1. Code pénal. Article 226-13. 2002. (Accessed 12 Sep 2018).
    1. Code pénal. Article 226-14. 2015. (Accessed 12 Sep 2018).
    1. International committee of Medical Journal Editors. Defining the role of authors and contributors (Accessed on 12 September 2018).

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel